Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Glucocorticoids for IgG4-RD
NCT05746689Not yet recruiting
- Sponsor
- Peking University International Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of sirolimus in IgG4-related disease (IgG4-RD), sponsored by Peking University International Hospital. Primary endpoint: Relapse Rate at 1 year. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05746689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746689.